Ultragenyx Pharmaceutical Inc RARE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:22 PM EDT
109.47quote price arrow up+0.22 (+0.20%)
Volume
417,449
52 week range
61.96 - 179.65

...

Loading . . .
  • Open104.06
  • Day High110.72
  • Day Low103.15
  • Prev Close109.25
  • 52 Week High179.65
  • 52 Week High Date12/24/20
  • 52 Week Low61.96
  • 52 Week Low Date05/13/20

Key Stats

  • Market Cap7.387B
  • Shares Out67.48M
  • 10 Day Average Volume0.52M
  • Dividend-
  • Dividend Yield-
  • Beta1.90
  • YTD % Change-21.06

KEY STATS

  • Open104.06
  • Day High110.72
  • Day Low103.15
  • Prev Close109.25
  • 52 Week High179.65
  • 52 Week High Date12/24/20
  • 52 Week Low61.96
  • 52 Week Low Date05/13/20
  • Market Cap7.387B
  • Shares Out67.48M
  • 10 Day Average Volume0.52M
  • Dividend-
  • Dividend Yield-
  • Beta1.90
  • YTD % Change-21.06

RATIOS/PROFITABILITY

  • EPS (TTM)-3.12
  • P/E (TTM)-35.08
  • Fwd P/E (NTM)-20.34
  • EBITDA (MRQ)-303.244M
  • ROE (MRQ)-24.49%
  • Revenue (MRQ)334.12M
  • Gross Margin (MRQ)95.56%
  • Net Margin (MRQ)-60.96%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date07/28/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ultragenyx Pharmaceutical Inc

There is no recent news for this security.

Profile

MORE
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23...
Daniel Welch
Chairman
Emil Kakkis M.D. Ph.D.
President
Mardi Dier
Chief Financial Officer
Dennis Huang
Executive Vice President
John Pinion II
Executive Vice President
Address
60 Leveroni Ct
Novato, CA
94949-5746
United States

Top Peers

SYMBOLLASTCHG%CHG
DNLI
Denali Therapeutics Inc
54.30+2.73+5.29%
HALO
Halozyme Therapeutics Inc
42.84-3.26-7.07%
NVTA
Invitae Corp
28.26+1.18+4.36%
NTRA
Natera Inc
91.44+0.85+0.94%
XLRN
Acceleron Pharma Inc
121.43+4.94+4.24%